Statin Medications and the Risk of Gynecomastia

Sean C. Skeldon; Bruce Carleton; James M. Brophy; Mohit Sodhi; Mahyar Etminan


Clin Endocrinol. 2018;89(4):470-473. 

In This Article


Our cohort included 6147 cases of gynecomastia and 61 470 corresponding matched controls. As expected more cases than controls had one of the conditions or medications associated with gynecomastia (Table 1). The adjusted RR was 1.19 (95% CI 1.04–1.36) for statin use 0–30 days prior to the index date, 1.38 (95% CI 1.15–1.65) for statin use 31–60 days prior to the index date and 1.20 (95% CI 1.03–1.40) 61–365 days prior to the index date (Table 2). The RR for current use of finasteride was 3.42 (95% CI: 2.36–4.94). The RR was similar for recent use and past use of finasteride (Table 2).